241 results
Page 6 of 13
8-K
EX-99.1
cxohfuqk42ld
11 Feb 21
Results of Operations and Financial Condition
7:05am
8-K
EX-99.1
gr75f 1eseb
11 Jan 21
Regulation FD Disclosure
7:00am
8-K
EX-99.1
aagh00 wxxk
6 Jan 21
Alkermes Announces Updates to Executive Leadership Team
4:24pm
8-K
EX-10.1
uzbmcax sndhvz
10 Dec 20
Alkermes Announces Strategic Value Enhancement Plan and Continued Board Refreshment
7:19am
8-K
EX-99.1
6p5h3 sxlfa
10 Dec 20
Alkermes Announces Strategic Value Enhancement Plan and Continued Board Refreshment
7:19am
8-K
EX-99.1
jhd8bq26jj 1oa3e1
17 Nov 20
Alkermes Receives FDA Complete Response Letter Related to ALKS 3831 Manufacturing Records Review
7:15am
8-K
EX-99.1
85oygu bxjo0uaa88
29 Oct 20
Alkermes plc Reports Third Quarter 2020 Financial Results and Raises 2020 Financial Expectations
7:06am
8-K
EX-99.2
06a 3fzn5
29 Oct 20
Alkermes plc Reports Third Quarter 2020 Financial Results and Raises 2020 Financial Expectations
7:06am
8-K
EX-99.1
1c9tt8
9 Oct 20
FDA Advisory Committee Votes in Support of ALKS 3831 for the Treatment of Schizophrenia and Bipolar I Disorder
5:20pm
8-K
EX-99.2
b1kg0rq2224mszuq
29 Jul 20
Alkermes plc Reports Second Quarter 2020 Financial Results and Issues 2020 Financial Expectations
7:08am
8-K
EX-99.1
h2ohi
29 Jul 20
Alkermes plc Reports Second Quarter 2020 Financial Results and Issues 2020 Financial Expectations
7:08am
8-K
EX-99.1
3vxxrxx
29 Apr 20
Alkermes Plc Reports First Quarter 2020 Financial Results and Provides COVID-19 Related Business Update
7:05am
8-K
EX-99.2
21pnd3x2v7oj48
29 Apr 20
Alkermes Plc Reports First Quarter 2020 Financial Results and Provides COVID-19 Related Business Update
7:05am
8-K
EX-99.1
edck8 kt0iyilgtg
13 Feb 20
Results of Operations and Financial Condition
7:06am
8-K
EX-99.2
j9zm4a
13 Feb 20
Results of Operations and Financial Condition
7:06am
8-K
EX-99.1
13zzri
13 Jan 20
Regulation FD Disclosure
7:07am